Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
- - - A new 2-year comparative study from NYU Langone just droppedand the results are clear: Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide): 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat) Even in per-protocol analysis (continuous GLP-1 use), surgery still outperformed: 24.6% vs 7.6% Surgery had better HbA1c improvement, too Translational Insight: Yes, the relatively low weight loss in the medication group was partly due to therapy interruptions and discontinuation
New insights into the mechanisms of chinese herbal products on diabetes: a focus on the bacteria-mucosal immunity-inflammation-diabetes axis
It is not approved for human consumption or medical application
Rather than viewing depletion as a single-variable issue, the session emphasized glutathione status as reflective of overall intracellular stress exposure
A mitochondrially encoded hormone ameliorates obesity and insulin resistance
There is currently no FDA-approved indication for tirzepatide specifically for Hashimoto's disease, and no large-scale randomized controlled trials have evaluated tirzepatide as a treatment for this autoimmune thyroid condition
US$ 27.82
US$ 22.09
US$ 25.03
US$ 29.10
US$ 20.72
US$ 20.51
US$ 20.11
